Cetuximab Augments Cytotoxicity with Poly (ADP-Ribose) Polymerase Inhibition in Head and Neck Cancer

Overexpression of the epidermal growth factor receptor (EGFR) is a hallmark of head and neck cancers and confers increased resistance and inferior survival rates. Despite targeted agents against EGFR, such as cetuximab (C225), almost half of treated patients fail this therapy, necessitating novel th...

Descripción completa

Detalles Bibliográficos
Autores principales: Nowsheen, Somaira, Bonner, James A., LoBuglio, Albert F., Trummell, Hoa, Whitley, Alexander C., Dobelbower, Michael C., Yang, Eddy S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3166164/
https://www.ncbi.nlm.nih.gov/pubmed/21912620
http://dx.doi.org/10.1371/journal.pone.0024148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3166164/
https://www.ncbi.nlm.nih.gov/pubmed/21912620
http://dx.doi.org/10.1371/journal.pone.0024148

Ejemplares similares